Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$0.48
EPS est.
$0.38
EPS surprise
+25.00%
1-day move
+6.26%
Repligen Corporation reported better-than-expected earnings per share, which likely contributed to the positive stock reaction of 6.26%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance. Investors may view the EPS beat as a sign of operational strength, but the lack of revenue data could raise questions about future growth prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.48 | $0.38 | +25.00% |
| Revenue | — | $192M | — |
No transcript is on record, and the analysis is based on numerical results only.
Repligen Corporation (RGEN) operates in the health care sector, specifically in life sciences tools and services. The company focuses on providing products and services that support the development and manufacturing of biologic drugs, which are increasingly important in modern medicine.
Last quarter
In the last quarter, Repligen reported an EPS of $0.49, exceeding expectations by 11.36%. However, the stock saw a slight decline the following day.
Management promises and guidance
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
+13.49%
Avg 1-day reaction
+3.37%
Analysts are cautiously optimistic about Repligen's upcoming earnings, expecting solid EPS and revenue figures. However, the market is also wary of potential misses given recent volatility.
Bull case
If Repligen beats expectations, it could signal strong demand for its products and a robust growth trajectory, potentially boosting investor confidence.
Bear case
Conversely, a miss on earnings or revenue could raise concerns about market demand and operational efficiency, leading to a negative reaction.
Key metrics to watch
EPS
0.38Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
192MTotal revenue reflects the company's sales performance and growth potential, which is critical for investor confidence.
The print will turn on these.
Q1
Will Repligen achieve an EPS of at least $0.38?
This figure is crucial for assessing the company's profitability and could influence investor sentiment significantly.
Q2
How does the revenue of $192M compare to previous quarters?
Revenue growth is a key indicator of business health and market demand, and any shortfall could raise concerns.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may underestimate Repligen's ability to leverage its product portfolio effectively, especially given recent innovations.
Supporting evidence
The company has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.
Options pricing suggests a significant move, indicating that traders expect volatility that may not align with consensus expectations.
Key risk
If the company reports revenue significantly below $192M, it could undermine the bullish sentiment.
Pre-commit to what would confirm each case.
The market is weighing the company's ability to sustain growth amidst increasing competition in the life sciences sector.
Bull confirmed if
An EPS of $0.40 or higher would confirm strong operational performance and investor confidence.
Bear confirmed if
An EPS below $0.37 would indicate potential issues in profitability and could lead to a sell-off.
What the market is pricing for the move.
Implied Move
±10.84%
Historical Avg
±5.7%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±13.3% while RGEN has averaged ±5.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
51.8%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$3.5M
18,481 sh
1 insider
Net
$3.5M
Net selling
Most Active Insiders· 4 open-market trades
$3.5M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
106.22%
of float
Insider
4.66%
of float
Holders
659
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
5,384,938 sh · $900.5M
9.54%
-10.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Repligen beats expectations, history suggests the stock could rise by an average of +3.57%, confirming a strong growth outlook.
In line / cautious
If results are in line with expectations, the stock may see a muted response as investors await further guidance.
Miss
A miss could lead to a decline in stock price, with history suggesting an average drop of +0.58% following such outcomes.
The lines on the call that would change the story.
Recent Transactions
Sep 24, 2026 · @ $190.00
8,404 sh
$1.6M
Sep 24, 2026 · @ $190.00
4,542 sh
$862,980.00
Oct 5, 2026 · @ $190.00
4,202 sh
$798,380.00
Oct 5, 2026 · @ $178.75
1,333 sh
$238,273.75
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
FMR, LLC
3,326,690 sh · $556.3M
5.89%
15.2%
United Capital Financial Advisors, LLC
2,790,650 sh · $466.7M
4.94%
0.6%
Vanguard Capital Management LLC
2,411,171 sh · $403.2M
4.27%
0.6%
Vanguard Portfolio Management LLC
2,312,825 sh · $386.8M
4.10%
0.3%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.